about
Cardiomyopathy and response to enzyme replacement therapy in a male mouse model for Fabry diseaseSubstrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry diseasePossible role of transforming growth factor-β1 and vascular endothelial growth factor in Fabry disease nephropathyEstablishing 3-nitrotyrosine as a biomarker for the vasculopathy of Fabry disease.A symptomatic Fabry disease mouse model generated by inducing globotriaosylceramide synthesis.Establishment and characterization of Fabry disease endothelial cells with an extended lifespan.Impaired proteolysis underlies autophagic dysfunction in Niemann-Pick type C diseaseDifferential involvement of COX1 and COX2 in the vasculopathy associated with the alpha-galactosidase A-knockout mouse.Decreased nitric oxide bioavailability in a mouse model of Fabry disease.Vascular dysfunction in the alpha-galactosidase A-knockout mouse is an endothelial cell-, plasma membrane-based defect.Neurological features of Fabry disease: clinical, pathophysiological aspects and therapy.Mapping mechanisms and charting the time course of premature cell senescence and apoptosis: lysosomal dysfunction and ganglioside accumulation in endothelial cells.Glycosphingolipid Mediated Caveolin-1 Oligomerization.α-Galactosidase-A Loaded-Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration.Caveolin-associated accumulation of globotriaosylceramide in the vascular endothelium of alpha-galactosidase A null mice.Globotriaosylceramide leads to K(Ca)3.1 channel dysfunction: a new insight into endothelial dysfunction in Fabry disease.
P2860
Q28730130-12281BAA-1271-493F-973B-65F96956033DQ28748170-1C0B8EFE-6EC8-4E43-8D14-7436B282F8EEQ33703845-421AEC88-2E41-4EFF-9342-4F71BF19C5D5Q33831482-7A45486E-788A-4127-BA4C-83C26D8C458CQ34159448-126F2039-A0FA-4B73-BA17-73A1F11A36D9Q36116909-BAB44A7B-76DB-422B-BD7A-81A6385C7EF2Q36714243-1EC534A2-2890-40B2-994A-F8366298F3EEQ37162532-97A52866-E057-4D4C-BFF7-7A603888DB9EQ37330561-6BA3754F-8AEB-4FE0-96EC-F69FF44F32E4Q37347258-64BFD8AD-F390-4DDD-B782-3C170911A672Q37994740-88D95286-7DDF-4BEC-9551-5DBBE5EA5B5FQ40069502-8E5553AA-AB93-475C-B0B1-6F04C3C8A88DQ42148671-724FA25D-F395-4CF3-BFCE-E90737C0A12DQ50255169-D7BD881D-8CFC-4A3C-B6D6-9B5F4299EBEBQ51797150-18F462C0-6487-4C43-8BFC-A007318B3039Q53453652-2A1373C9-7130-4004-A4D0-B2940037A8EA
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
An in vitro model of Fabry disease.
@en
An in vitro model of Fabry disease.
@nl
type
label
An in vitro model of Fabry disease.
@en
An in vitro model of Fabry disease.
@nl
prefLabel
An in vitro model of Fabry disease.
@en
An in vitro model of Fabry disease.
@nl
P2093
P356
P1476
An in vitro model of Fabry disease.
@en
P2093
Hedwig S Murphy
James A Shayman
Laura Cooling
Liming Shu
P304
P356
10.1681/ASN.2005040383
P577
2005-07-20T00:00:00Z